Reata Pharmaceuticals ( NASDAQ:RETA – Get Rating ) had its price target hoisted by Stifel Nicolaus from $75.00 to $105.00 in a report issued on Wednesday morning, The Fly reports. Several other equities research analysts have also recently commented on RETA. Robert W. Baird boosted their target price on Reata Pharmaceuticals from $40.00 to $85.00 and gave the stock a neutral rating in a report on Wednesday. Cantor Fitzgerald boosted their target price on Reata Pharmaceuticals from $61.00 to $121.

https://www.dailypolitical.com/2023/03/05/reata-pharmaceuticals-nasdaqreta-pt-raised-to-105-00-at-stifel-nicolaus.html

#dailypolitical